In silico modeling of phosphorylation dependent and independent c-Myc degradation

[1]  Sukhen Das Mandal,et al.  MYCbase: a database of functional sites and biochemical properties of Myc in both normal and cancer cells , 2017, BMC Bioinformatics.

[2]  Lan K. Nguyen,et al.  Dynamics of ubiquitin-mediated signalling: insights from mathematical modelling and experimental studies , 2016, Briefings Bioinform..

[3]  Srijeeta Talukder,et al.  Deciphering Parameter Sensitivity in the BvgAS Signal Transduction , 2016, PloS one.

[4]  G. Rangarajan,et al.  Disorder, oscillatory dynamics and state switching: the role of c-Myc. , 2015, Journal of theoretical biology.

[5]  Walter Kolch,et al.  When ubiquitination meets phosphorylation: a systems biology perspective of EGFR/MAPK signalling , 2013, Cell Communication and Signaling.

[6]  Z. Qu,et al.  Roles of Protein Ubiquitination and Degradation Kinetics in Biological Oscillations , 2012, PloS one.

[7]  Chi V Dang,et al.  MYC on the Path to Cancer , 2012, Cell.

[8]  S. Murray,et al.  myc maintains embryonic stem cell pluripotency and self-renewal. , 2010, Differentiation; research in biological diversity.

[9]  Guang Yao,et al.  Sensing and Integration of Erk and PI3K Signals by Myc , 2008, PLoS Comput. Biol..

[10]  Amit Kumar,et al.  Phosphoinositide 3-Kinase Activation in Late G1 Is Required for c-Myc Stabilization and S Phase Entry , 2006, Molecular and Cellular Biology.

[11]  Shinya Kuroda,et al.  Prediction and validation of the distinct dynamics of transient and sustained ERK activation , 2005, Nature Cell Biology.

[12]  John J Tyson,et al.  A model for restriction point control of the mammalian cell cycle. , 2004, Journal of theoretical biology.

[13]  K. Nakayama,et al.  Phosphorylation‐dependent degradation of c‐Myc is mediated by the F‐box protein Fbw7 , 2004, The EMBO journal.

[14]  Joseph R. Nevins,et al.  A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells , 2004, Nature Cell Biology.

[15]  K. Nakayama,et al.  The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. , 2003, Molecular cell.

[16]  S. Kim,et al.  Skp2 regulates Myc protein stability and activity. , 2003, Molecular cell.

[17]  S. Reed,et al.  hCDC4 gene mutations in endometrial cancer. , 2002, Cancer research.

[18]  K. Nakayama,et al.  Degradation of p27 Kip1 at the G0-G1 Transition Mediated by a Skp2-independent Ubiquitination Pathway* , 2001, The Journal of Biological Chemistry.

[19]  S. Elledge,et al.  Phosphorylation-Dependent Ubiquitination of Cyclin E by the SCFFbw7 Ubiquitin Ligase , 2001, Science.

[20]  M. Gregory,et al.  c-Myc Proteolysis by the Ubiquitin-Proteasome Pathway: Stabilization of c-Myc in Burkitt's Lymphoma Cells , 2000, Molecular and Cellular Biology.

[21]  L. Larsson,et al.  c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. , 2000, Blood.

[22]  Michele Pagano,et al.  SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27 , 1999, Nature Cell Biology.

[23]  S. Elledge,et al.  The role of protein stability in the cell cycle and cancer. , 1998, Biochimica et biophysica acta.

[24]  C. Dang,et al.  Role of Oncogenic Transcription Factor c-Myc in Cell Cycle Regulation, Apoptosis and Metabolism. , 1997, Journal of biomedical science.

[25]  S. Leibler,et al.  Robustness in simple biochemical networks , 1997, Nature.

[26]  B. Lutterbach,et al.  Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis , 1994, Molecular and cellular biology.

[27]  R. Eisenman,et al.  Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells , 1984, Molecular and cellular biology.

[28]  C. Croce,et al.  Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Sears,et al.  MYC degradation. , 2014, Cold Spring Harbor perspectives in medicine.

[30]  Aaron Ciechanover,et al.  Proteolysis: from the lysosome to ubiquitin and the proteasome , 2005, Nature Reviews Molecular Cell Biology.

[31]  Michele Pagano,et al.  Aberrant ubiquitin-mediated proteolysis of cell cycle regulatory proteins and oncogenesis. , 2003, Advances in cancer research.

[32]  L. Penn,et al.  The myc Oncogene: omplex , 2002 .

[33]  R. Eisenman,et al.  The Myc/Max/Mad network and the transcriptional control of cell behavior. , 2000, Annual review of cell and developmental biology.

[34]  A. Ciechanover,et al.  Degradation of MYCN oncoprotein by the ubiquitin system. , 1991, Progress in clinical and biological research.